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Abstract
Background: rs10911021 (a single nucleotide polymorphism present upstream of the GLUL gene) affects glutamic
acid metabolism, and was shown to be associated with coronary heart disease (CHD) in patients with T2DM but a
definite mechanism is unknown. It may affect glutathione cycle, an important effector in the antioxidant defense
mechanism, in the cells. We checked the association of this SNP with CHD and oxidative stress biomarkers,
malondialdeheyde (MDA), GSH and GSSG in Pakistani patients.
Methods: A total of 650 subjects (425 CHD cases and 225 controls) were genotyped by TaqMan allelic
discrimination technique. The levels of MDA, GSH and GSSG were measured by standard protocols.
Results: The risk allele frequency was higher in cases than controls, but the difference was insignificant (p = 0.55).
The SNP was not associated with CHD (p = 0.053) but when the analysis was limited to CHD patients having DM, a
significant association (p = 0.03) was observed. The blood levels of MDA and GSSG were higher while that of GSH
was significantly lower in the cases than the controls (p < 0.05). Each risk allele increased MDA and GSSG by 0.29 (0.
036) mmol/l and 0.4 (0.04) mmol/l, respectively, while decreased GSH by −0.36 (0.03) mmol/l. The SNP was not
associated with any of the tested blood lipids.
Conclusion: The SNP rs10911021 was associated with CHD only in patients having diabetes, but the SNP was
associated with total oxidative stress biomarkers MDA and GSH and GSSG levels. As the SNP rs10911021 showed
significant association with oxidative stress parameters and these parameters should an increased oxidative stress in
the CHD subjects, it can be concluded that the SNP may have contributed to increase the risk of heart diseases in
the diabetic subjects by increasing the oxidative stress.
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Background
Oxidative stress results from an imbalance between the
production of oxidants and their clearance by antioxi-
dant defence mechanism [1]. The reactive oxygen spe-
cies (ROS) are free radicals produced during aerobic
respiration and being highly unstable, react with certain
cell components like lipids, proteins and nucleic acids
[2, 3]. Body has antioxidant defence mechanism consist-
ing of antioxidant molecules like glutathione and en-
zymes like super oxide dismutase, glutathione reductase,
catalase and glutathione peroxidase to cope up with oxi-
dative stress. Among the biomolecules, lipids are most
vulnerable to oxidative stress. Lipids such as membrane
polyunsaturated fatty acids and low-density lipoprotein
cholesterol (LDL-C) are main targets. Lipid peroxidation
leads to formation of lipid hydroperoxides which break-
down to aldehydes through a chain of reaction [4]. Alde-
hydes are relatively stable compared to the free radicals
and can diffuse from their site of synthesis to react with
other cell components [5].
The direct approach for the determination of oxidative
stress is either the measurement of free radicals or the ex-
tent of lipid peroxidation. The lipid peroxidation cannot
be measured by the concentration of primary products
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(hydroperoxides) because of the labile nature of free radi-
cals which may be ROS or hydroperoxides. Consequently,
the lipid peroxidation determination relies on the indirect
approach which is the measurement of secondary end
products, aldehydes [6]. The most commonly used bio-
marker as an index of lipid peroxidation is Malondialde-
hyde (MDA), a naturally occurring relatively stable and
low molecular weight end product of membrane lipids
peroxidation produced along other byproducts [7]. MDA
itself is a colourless end product which is measured in
terms of thiobarbituric acid reactive substances (TBARS)
through the thiobarbituric acid (TBA) test.
The oxidative stress can also be estimated by the status of
antioxidant system in body. Glutathione, a tripeptide con-
sisting of cysteine, glutamic acid and glycine is a ubiquitous
molecule in living system. Reduced glutathione (GSH) is
present mainly in free form and is converted to oxidized
form (GSSG) by enzyme GSH peroxidase during the oxida-
tive stress. The oxidized form is converted back to reduced
form by the enzyme GSSG reductase. The synthesis and
breakdown of glutathione takes place by the ɣ- glutamyle
reaction. The glutathione cycle with its associated enzymes,
glutathione peroxidase and glutathione reductase serves to
maintain the overall oxidative milieu of the cell [8]. The
redox status of the cell depends upon the relative concen-
trations of GSH and GSSG [9]. Because glutathione pro-
tects the cell from oxidative stress, its availability in
reduced form is mandatory to control the redox status of
the cell. Because blood glutathione level is an index of
glutathione status in other less accessible tissues, red blood
cell glutathione is considered to represent whole body
glutathione status [10].
There is growing evidence that oxidative stress causes
many chronic ailments like aging, diabetes [11], Alzhei-
mer’s disease, infertility [12] and cardiovascular diseases
[13]. Many studies have investigated the causal link be-
tween oxidative stress and CHD as the administration of
antioxidants relived from the cardiac cell injury [14–16].
The SNP rs10911021 is an intergenic C/T variant, located
nearby glutamate-amonia ligase (GLUL) gene and was
found to downregulate the gene [17]. The GLUL is located
at 1q31 and encodes glutamate ammonia ligase (glutamine
synthetase) enzyme involved in glutathione biosynthesis.
The enzyme inefficiency (deficiency or impaired function)
may cause deficiency of glutamine and glutathione synthe-
tase. Glutamine is an abundant aminoacid used in the bio-
synthesis of other aminoacids and glutathione [17].
The SNP rs10911021 which affects glutamic acid me-
tabolism was reported to be associated with coronary
heart disease (CHD) in subjects having type 2 diabetes
mellitus (T2DM) although no definite mechanism was
proposed [17, 18]. We proposed that the risk allele may
cause CHD due to oxidative stress by interfering with
the intermediates of glutathione cycle. The objective of
this study was to investigate the effect of this SNP on
oxidation status of the body. For this purpose GSH and
GSSG levels were measured as indicators of oxidation
status and the lipid oxidation end product, MDA, was
used as an index of oxidation stress.
Methods
Study subjects
The study consisted of 425 CHD patients and 225 con-
trols as described previously [19]. The CHD cases were
ischemic heart disease patients diagnosed on the bases
of ECG, cardiac echo, radiological and biochemical re-
ports. All cases were recently diagnosed, not taking any
lipid lowering or anti-hypertensive drugs. Controls were
age and sex matched individuals without any history of
cardiovascular disease. Among CHD patient, 275 had
type 2 diabetes and among controls, 30 subjects were
diabetic. The participants gave a written consent and the
study was approved by the institutional ethical commit-
tee, University of the Punjab, Lahore.
Determination of GSH and GSSG
The red cell GSH and GSSG were measured from red
cell haemolysate, prepared from fresh blood. Briefly,
300 μl of well mixed fresh whole blood was mixed with
double amount of cold sterilized normal saline and cen-
trifuged at 4000 g for 2 min. Supernatant was discarded
and red cell pellet was resuspended in the residual fluid.
The cells were washed thrice in the same way with nor-
mal saline. A 500 μl of ice cold autoclaved distilled water
was added to washed RBCs and mixed with the help of
vortex mixer. The lysate was centrifuged at 10,000 g for
5 min to pellet down RBC membranes (ghost cells). The
lysate was put on ice during subsequent analyses.
Red cell GSH and GSSG levels were measured using
Ellman’s reagent by the reduction of 5, 5ˊ- dithiobis-2-
nitrobenzoic acid (DNTB) as described previously [20].
The reaction buffer consisted of 0.1 M PO4 buffer
(pH 7), 0.5 mM EDTA and low concentration of DNTB
(3 mM) in absolute ethanol. A 10 mM nicotineamide di-
nucleotide phosphate hydrogen (NADPH) and 1 unit of
glutathione reductase was used. All the reagents and en-
zyme was purchased from Sigma Aldrich (USA).
Determination of malondialdehyde
The MDA concentration was measured as thiobarbituric
acid reactive substances (TBARS) according to Ozturk
et al. [21]. The method depends upon the precipitation
of proteins, bilirubin, lipoproteins and other interfering
substances by boiling in trichloroacetic acid (TCA). The
assay mixture consisted of 10% TCA and 0.8% TBA. Bu-
tylated hydroxyl toluene (BHT) was used to reduce oxi-
dation during the heating process.
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Genotyping rs10911021
Genomic DNA was extracted from peripheral blood using
Promega Wizard® genomic DNA purification kit. The
DNA was quantified using nanodrop (ND-8000, USA)
and diluted to a standard concentration of 1.25 ng/μl. A
4 μl of this dilution was used to get the final working con-
centration of 5 ng of DNA. A liquid handling robotic sys-
tem (Biomerk FX, Beckman Coulter) was used to spot
DNA in 384 well plates (Micro Amp). After spotting the
dilution was allowed to evaporate at room temperature to
get DNA in dried form.
The genotyping was done by the TaqMan allelic dis-
crimination technique. The reaction mixture consisted
of 1X qPCR master mix (KAPABiosystems, USA),
100 nM of each primer, 100 nM of each probe, ROX
high (0.4 μl/20 μl reaction mixture), 5 ng DNA in dried
form and sigma water as required. The PCR program
run on thermal cycler BioRad (C1000TM) consisted of
an initial temperature of 50 °C for 2 min, denaturation/
enzyme activation at 95 °C for 10 min followed by amp-
lification for 40 cycles each cycle consisting of denatur-
ation at 95 °C for 15 s and amplification at 60 °C for
1 min. After amplification the results were analyzed on
ABI Prism 7900HT (Applied Biosystems/Life Technolo-
gies) and the genotypes were called using sequence de-
tection software (SDS version 2.0). The genotypes were
also confirmed randomly by conventional direct DNA
sequencing (source biosciences, UK) to check the accur-
acy of technique and the results were concordant.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS version 22, IBM statis-
tics). The study population was checked for Hardy
Weinberg equilibrium (HWE) by Chi-square test. The stu-
dent t-test was used to compare variables between case and
control groups. Allele and genotype frequencies were calcu-
lated by an excel spreadsheet and chi-square test was used
to compare allele frequencies between cases and controls.
The association of genotypes with CHD was checked by
binary logistic regression. The mean MDA, GSH and GSSG
values for each genotype was calculated by ANOVA and
their increase per allele was calculated by linear regression.
An online power calculator (https://www.dssresearch.com/
KnowledgeCenter/toolkitcalculators/statisticalpowercalcula-
tors.aspx) and G Power software were used for power ana-




The general characteristics of the subjects included in the
study are listed in Table 1. The proportion of males and fe-
males did not differ significantly among the participants.
The mean age of cases (59.07 ± 12.66) and controls (55.97
± 10.42) differed significantly (p = 0.002). The proportion of
comorbidities, including diabetes, hypertension and obesity
was higher in CHD cases than controls. The serum total
cholesterol, LDL-C and triglyceride levels were higher and
high density lipoprotein cholesterol (HDL-C) was lower in
CHD cases than controls. The mean weight, BMI and
WHR for obese subjects were 96.16 ± 15.95, 36.92 ± 6.46
and 1.00 ± 0.09 respectively, for CHD subjects were 67.13
± 11.95, 22.46 ± 6.75 and 0.81 ± 0.06 respectively and for
control subjects 67.13 ± 9.56, 21.46 ± 9.11 and 0.85 ± 0.10
respectively. The study power assuming a standard devi-
ation of 1 and with a sample size of 650 was 81%.
Allele and genotype frequencies of rs10911021
The allele and genotype frequencies of the rs10911021
variant are shown in Table 2. The risk allele (C) fre-
quency (RAFs) in CAD group was higher than controls
(0.678 vs 0.624), although the difference was not statisti-
cally significant (p = 0.055). Genotype distribution re-
vealed following distribution among the cases and
controls (CHD: CC = 45.3%, CT = 45%, TT = 9.7%; vs
controls CC = 38.5%, CT = 48%, TT = 13.6%). The SNP
was not associated with CHD, OR 1.3 (1–1.6. p = 0.05)
but when the analysis was limited to diabetic subjects
(275 T2DM patients out of 425 CHD patients) only, a
significant association was observed (p = 0.03).
Blood levels of oxidative stress biomarkers
To check the significance of difference of the blood
levels of oxidative stress indicators between the cases
and the controls, student t-test was used. A two tailed
test showed that the mean MDA and GSSG were signifi-
cantly higher while mean GSH was lower in cases than
controls in cases than controls. The association of each
parameter with CHD was checked using binary logistic
Table 1 General characteristics of the study population, continuous
variables are expressed as mean ± SD and categorical variables are
expreesed as %
Variables Cases (425) Controls (225) p-value
Gender (M/F) 250/175 122/103 0.271
Age (years) 59.11 ± 12.64 56.01 ± 10.44 0.002
Diabetes (%) 275 (64.6) 30 (13.6) 5.1 × 10−34
Hypertension (%) 264 (62.1) 37 (16.4) 8.9 × 10−28
TC 207.5 ± 53.65 175.4 ± 43 <0.001
LDL-C 105.95 ± 28.9 84.7 ± 16.9 <0.001
HDL-C 45.2 ± 11.9 67.4 ± 16.3 <0.001
TG 212.4 ± 70 188 ± 66.3 <0.001
TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high
density lipoprotein cholesterol, TG triglycerides, p value: level of
statistical significance
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regression and all these parameters were found to be as-
sociated with CHD (Table 3).
Effect of rs10911021 polymorphism on oxidative stress
biomarkers
A steady increase in the mean MDA and GSSG and a
decrease in mean GSH from wild type homozygous to
heterozygous to the homozygous polymorphic genotype
was observed. Linear regression was employed to deter-
mine the per risk allele increase/decrease in the mean
oxidative stress parameters. The p-values indicate that
the presence of the risk allele is strongly associated with
the increase in TBARS/GSSG and decrease in GSH in
the studied subjects (Table 4).
Discussion
Serum thiobarbituric acid reactive substance (TBARS)
measurement is a relatively nonspecific indicator of oxi-
dative stress as the MDA is neither the sole end product
of lipid peroxidation nor it is an exclusive product of
fatty acid oxidation. MDA can also react with com-
pounds other than TBA and MDA can also be produced
from other compounds and during heating process while
MDA measurement [22]. This phenomenon was ad-
dressed by the addition of BHT in the reaction mixture.
The variant rs10911021 is a new locus identified to be
associated with diabetes in subjects with coronary heart
disease [17]. Since its identification, only a few studies
have investigated its role in different diseases. One study
identified this variant to be a predictor of all cause mor-
tality in diabetic subjects [18]. This intergenic SNP is
approximately 270 Kb from the gene encoding glutamate
ammonia ligase (GLUL) enzyme belonging to the
glutamine synthase family. It has been found that
individuals homozygous for the risk allele (C) have a
lower plasma pyroglutamic acid/glutamic acid ratio
resulting in impairment of the γ-glutamyl cycle which
consequently increases oxidative predisposing diabetic
individuals to CHD [17].
The GLUL also known as glutamine synthase catalyzes
the conversion of glutamic acid (Glu) and ammonia into
glutamine (Gln) [23]. Both Glu and Gln play important
roles in human physiology. Glu is a key intermediate of
the γ-glutamyl cycle which produces the anti-oxidant
glutathione [24] while Gln regulates many important cell
processes including cell proliferation, inhibition of apop-
tosis, and cell signalling [25]. Gln has been proved to be
cardioprotective when administered enterally and para-
enterally in many clinical trials [26, 27].
In the current study, we observed a directionally con-
sistent association of the risk allele wth the diabetes in
CHD patients. The minor allele showed to be the pro-
tective allele in the current study as well as previous
studies. Although the observed association was not sta-
tistically significant, the power analysis showed that we
had 81% power to detect the effect observed by Qi et al.
Abnormal metabolism of glutamate and glutamine has
been shown to be related to insulin resistance, type 2
diabetes, and cardiovascular diseases in many epidemio-
logical studies [28–30]. The mechanism through which
the changes in metabolism of these amino acids can lead
to increased CHD risk is unclear at present. However,
the proposed mechanisms are based on the understand-
ing of alterations of glutamate and glutamine metabol-
ism physiological pathways, the consequences that one
would expect from the reduced GLUL expression. This
in turn may affect glutathione cycle and the antioxidant
defense mechanism in the cells.




Overall subjects Diabetic Subjects only
Cases (425) Controls (225) p-value Cases (275) Controls (30) p-value
TT 9.7 13.6 0.053 16.1 6.3 0.034
TC 45 48 36.7 33.3
CC 45.3 38.5 47.2 60.4
T 32.2 37.6 20.7 34.4
C 67.8 62.4 79.3 65.6
Table 3 comparison of MDA, GSH and GSSG among cases and controls and their CHD OR
Variables Cases Controls P value OR (CI) p-value
TBARS mmol/l 3.15 ± 0.65 2.89 ± 0.51 4.2 × 10−7 2 (1.5–2.6) <0.001
GSH mmol/l 5.4 ± 0.46 5.9 ± 0.48 6.7 × 10−35 0.8 (0.78–0.85) <0.001
GSSG mmol/l 4.31 ± 0.62 3.80 ± 0.50 5.1 × 10−24 4.8 (3.4–6.8) <0.001
OR odds ratio, CI confidence of interval
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We observed significantly different blood levels of
MDA, GSH and GSSG between the cases and controls
with GSH levels lower while that of MDA and GSSG
higher in the cases compared to the controls indicating
an overall oxidative stress in the CHD patients. It has
been reported previously that decreased activity of anti-
oxidant enzymes is associated with increased oxidative
stress and vascular endothelium dysfunction in patient
with chronic heart failure [31]. In addition, this oxidative
stress affects other organs as well including pancreas ul-
timately causing islet damage leading to diabetes [32].
The increased oxidative stress in CHD patients can
therefore lead to diabetes.
The SNP rs10911021 did not show association with the
risk of type 2 diabetes in Diabetes Genetics Replication
and Meta-analysis Consortium (DIAGRAM) study, which
suggested that the association of the variant with CHD in-
volves mechanism distinct from that in type 2 diabetes
[33]. In addition, the variant did not show association with
the serum fasting insulin or glucose levels, rejecting the
hypothesis that insulin resistance can be the underlying
mechanism [34]. However, it was associated with a lower
plasma pyroglutamic-to-glutamic acid ratio, suggesting a
possible mechanism for increase in CHD risk by lowering
the serum level of the natural antioxidant glutathione.
This association has also been replicated in the KORA/
Twins UK metabolomic databases (p = 0.00096 in KORA
(https://www.helmholtz-muenchen.de/ibis/research/meta
bolomics/projects/index.html). It should be noticed that
additional pathways that are not directly related to glu-
tamate and glutamine may also contribute to vascular
biology and atherogenesis, e.g., a variety of lysophospholi-
pids were found to be associated with rs10911021 in some
databases [33, 35, 36]. In future, further studies are
therefore needed to identify the mechanisms underlying
the effect of this locus in the development and progres-
sion of heart issues.
The limitations of the study included a relatively small
sample size and inability to include more biochemical
and anthropometric measures in order to observe the
real behaviour of the variant in the Pakistani ethnic
group. The findings of the study should be therefore
replicated in larger cohorts in the future with more bio-
chemical parameter included in order to validate the re-
sults observed in the current investigation and find out
new associations, if any, of the variant.
Conclusion
In conclusion, the SNP rs10911021 was associated
with CHD only in patients having DM, but the SNP
was associated with total oxidation stress biomarker
MDA and GSH and GSSG values. Therefore,
rs10911021 can increase the risk of heart diseases in
the diabetic subjects by increasing the oxidative
stress in the endothelial system.
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